Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Currently, there is no biochemical marker clinically available to test for the presence of Alzheimer's disease (AD). Recent studies suggest that the core component of AD-associated neurofibrillary tangles (NFTs), the microtubule-associated protein tau, might be present in CSF. This study focuses on establishing both the presence of tau in CSF and its potential utility in the diagnosis of AD. We obtained CSF from 181 individuals; 71 of these were diagnosed as having probable AD by NINCDS-ADRDA criteria. The remaining 110 individuals were divided into three groups: (1) age-matched demented non-AD patients (n = 25), (2) neurologic controls (n = 59), and (3) other controls (n = 26). We developed a sensitive enzyme-linked immunosorbent tau assay using monoclonal antibodies prepared against recombinant human tau. We confirmed specificity of the antibodies by a combination of immunoprecipitation and immunoblot results. By this assay we measured that the AD population has a mean level of tau 50% greater than the non-AD dementia patients. Comparing AD patients with all other groups, the difference in tau levels as analyzed by one-way ANOVA is highly statistically significant (p < 0.001). Postmortem analysis of two AD patients with high levels of CSF tau revealed a high density of NFTs in the hippocampus. There was no significant correlation between tau and age in the non-AD groups. This study suggests that CSF tau is elevated in AD and might be a useful aid in antemortem diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overexpression of tau in a nonneuronal cell induces long cellular processes.
Knops, J., Kosik, K. S., Lee, G., Pardee, J. D., Cohen-Gould, L., & McConlogue, L. (1991) · The Journal of cell biology · doi:10.1083/jcb.114.4.725 · Cited by 286
Cited by
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 953
Tau protein and the neurofibrillary pathology of Alzheimer's disease
Goedert, M. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90078-z · Cited by 716
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Self-citationChen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 673
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509
Protein oxidation in the brain in Alzheimer's disease
Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., Geddes, J. W., & Markesbery, W. R. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00580-7 · Cited by 503
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.213 · Cited by 477
TAR DNA-binding protein 43 in neurodegenerative disease
Chen-Plotkin, A. S., Lee, V. M.-Y., & Trojanowski, J. Q. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.18 · Cited by 468
A current view on Tau protein phosphorylation in Alzheimer's disease
Wegmann, S., Biernat, J., & Mandelkow, E. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.03.003 · Cited by 456
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450
Bacskai, B. J., Kajdasz, S. T., Christie, R. H., Carter, C., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2001) · Nature Medicine · doi:10.1038/85525 · Cited by 449
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citationSjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436
Microtubule-associated protein tau in development, degeneration and protection of neurons
Wang, J.-Z., & Liu, F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.002 · Cited by 398
Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 341
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury
Öst, M., Nylén, K., Csajbok, L., Öhrfelt, A. O., Tullberg, M., Wikkelsö, C., Nellgård, P., Rosengren, L., Blennow, K., & Nellgård, B. (2006) · Neurology · doi:10.1212/01.wnl.0000242732.06714.0f · Cited by 321
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease
Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz–Schaeffer, W., Kretzschmar, H. A., & Poser, S. (2002) · Neurology · doi:10.1212/wnl.58.2.192 · Cited by 289
CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease
Blennow, K., Vanmechelen, E., & Hampel, H. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:087 · Cited by 267
Both total and phosphorylated tau are increased in Alzheimer's disease
Sjogren, M. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.624 · Cited by 253
Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease
Roses, A. D. (1995) · Annals of Neurology · doi:10.1002/ana.410380105 · Cited by 252
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis
Kasai, T., Tokuda, T., Ishigami, N., Sasayama, H., Foulds, P., Mitchell, D. J., Mann, D. M. A., Allsop, D., & Nakagawa, M. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0456-1 · Cited by 211
Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Arai, H., Morikawa, Y.-I., Higuchi, M., Matsui, T., Clark, C. M., Miura, M., Machida, N., Lee, V. M.-Y., Trojanowski, J. Q., & Sasaki, H. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6908 · Cited by 159
CSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151
CSF tau and β-amyloid as biomarkers for mild cognitive impairment
Hampel, H., & Blennow, K. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.4/hhampel · Cited by 52
Analysis of Human Tau in Cerebrospinal Fluid
Hanisch, K., Soininen, H., Alafuzoff, I., & Hoffmann, R. (2010) · Journal of Proteome Research · doi:10.1021/pr901002t · Cited by 17
Metadata
- Authors
- Vigo-Pelfrey, C., Seubert, P. P., Barbour, R., Blomquist, C., Lee, M., Lee, D., Coria, F., Chang, L., Miller, B., Lieberburg, I., & Schenk, D.
- Venue
- Neurology
- Published
- 1995-04
- Volume
- 45
- Issue
- 4
- Pages
- 788-793
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2013764865
- Cited by
- 225
- References
- 1
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.